Company profile
Spexis AG (Polyphor AG)
Spexis AG (SIX:SPEX) is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancer. Spexis was created in December 2021 through the merger of EnBiotix, Inc., a privately held US biotech, into Polyphor AG, a publicly listed Swiss biotechnology company.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
